L. Benito

发表

Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations

C. Lázaro, G. Capellá, E. Serra, 2009, Human mutation.

Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment

C. Lázaro, G. Capellá, E. Serra, 2010, European Journal of Human Genetics.

A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1‐splice mutation and the presence of a complex mosaicism

C. Lázaro, G. Capellá, E. Serra, 2011, Human mutation.

Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (–), CD14 (–), and CD33 (–)

L. Benito, J. G. García Vela, M. Martín, 1999, Annals of Hematology.

MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study

S. Gruber, C. Lázaro, G. Capellá, 2012, European Journal of Human Genetics.

Dissecting Loss of Heterozygosity (LOH) in Neurofibromatosis Type 1-Associated Neurofibromas: Importance of Copy Neutral LOH

C. Lázaro, G. Capellá, H. Kehrer-Sawatzki, 2010, Human mutation.

Aberrant Immunophenotypes Detected by Flow Cytometry in Acute Lymphoblastic Leukemia

L. Benito, J. G. García Vela, I. Delgado, 2000, Leukemia & lymphoma.

Detection of minimal residual disease in B-cell chronic lymphocytic leukaemia by flow cytometry.

L. Benito, J. G. García Vela, I. Delgado, 1997, British journal of haematology.

CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection

L. Benito, I. Delgado, M. Monteserin, 1999, Leukemia.